Share chart Vir Biotechnology, Inc.
Extended chart
Simple chart
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., компания, занимающаяся иммунологией на клинической стадии, разрабатывает терапевтические продукты для лечения и профилактики серьезных инфекционных заболеваний. Он разрабатывает VIR-2218 и VIR-3434 для лечения вируса гепатита B; VIR-2482 для профилактики вируса гриппа A; VIR-1111 для профилактики вируса иммунодефицита человека; и ВИР-2020 для профилактики туберкулеза. more details| IPO date | 2019-10-11 |
|---|---|
| ISIN | US92764N1028 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.vir.bio |
| Цена ао | 6.95 |
| Change price per day: | +4.73% (5.28) |
|---|---|
| Change price per week: | -0.8961% (5.58) |
| Change price per month: | -24.51% (7.325) |
| Change price per 3 month: | -54.3% (12.1) |
| Change price per half year: | -27.9% (7.67) |
| Change price per year: | -38.35% (8.97) |
| Change price per 3 year: | -74.37% (21.58) |
| Change price per 5 year: | -89.56% (52.95) |
| Change price per year to date: | -22.71% (7.155) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Blackrock Inc. | 16864579 | 12.54 |
| SB INVESTMENT ADVISERS (UK) LTD | 16684041 | 12.4 |
| Vanguard Group Inc | 12297139 | 9.14 |
| State Street Corporation | 6912082 | 5.14 |
| Baillie Gifford and Company | 3965549 | 2.95 |
| Citadel Advisors Llc | 3037948 | 2.26 |
| AllianceBernstein L.P. | 2781049 | 2.07 |
| Morgan Stanley | 2126279 | 1.58 |
| Geode Capital Management, LLC | 1886396 | 1.4 |
| Bill & Melinda Gates Foundation | 1559142 | 1.16 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Amplify Treatments Testing and Advancements ETF | 3.14 | 10.31 | 1.06 |
| AGFiQ US Market Neutral Momentum Fund | 1.09 | -16.42 | 2.58 |
| Syntax Stratified SmallCap ETF | 0.11777 | 13.51 | 1.639 |
| Future Tech ETF | 0.1033 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.1033 | 618.5 | 0.8416 |
| Pacer BioThreat Strategy ETF | 0.03864 | 15.84 | 1.65371 |
| iShares Morningstar Small-Cap Value ETF | 0.03119 | 197.28 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.01572 | 391.25 | 1.60498 |
| 0.58 | 207.08 | 1.59 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 177.66k | 1960 (65 years) |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | N/A | |
| Dr. Ann M. Hanly Ph.D. | Executive VP & Chief Technology Officer | 842.23k | 1970 (55 years) |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | N/A | 1947 (78 years) |
| Ms. Heather Rowe Armstrong | Vice President of Investor Relations | N/A | |
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | N/A | 1969 (56 years) |
| Ms. Vanina De Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | N/A | |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | N/A | |
| Dr. Jeff Calcagno M.D. | Executive VP & Chief Business Officer | 1961 (64 years) | |
| Ms. Arran Attridge | Senior Vice President of Corporate Communications |
Address: United States, San Francisco, 499 Illinois Street - open in Google maps, open in Yandex maps
Website: https://www.vir.bio
Website: https://www.vir.bio
